{"pageContent": "Purpose of review: The field of prostate cancer therapeutics has undergone a rapid and dramatic change in the last few years. Multiple agents with very distinct mechanisms of actions and unique toxicities and efficacies have become available for clinical use. The focus of this review is to give a summary of clinical perspectives of the indications, including pros and cons of the currently approved regimens. The next generation of novel targets and agents is also highlighted.", "metaData": {"source": "Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy\nhttps://pubmed.ncbi.nlm.nih.gov/23065626/"}}